[go: up one dir, main page]

EA201792080A1 - Гуманизированные анти-c1s антитела и способы их применения - Google Patents

Гуманизированные анти-c1s антитела и способы их применения

Info

Publication number
EA201792080A1
EA201792080A1 EA201792080A EA201792080A EA201792080A1 EA 201792080 A1 EA201792080 A1 EA 201792080A1 EA 201792080 A EA201792080 A EA 201792080A EA 201792080 A EA201792080 A EA 201792080A EA 201792080 A1 EA201792080 A1 EA 201792080A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
humanized anti
present
methods
application
Prior art date
Application number
EA201792080A
Other languages
English (en)
Inventor
Сандип Паникер
Грэм Пэрри
Original Assignee
БИОВЕРАТИВ ЮЭсЭй ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by БИОВЕРАТИВ ЮЭсЭй ИНК. filed Critical БИОВЕРАТИВ ЮЭсЭй ИНК.
Publication of EA201792080A1 publication Critical patent/EA201792080A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21106—Hepsin (3.4.21.106)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

В данном изобретении предложены гуманизированные анти-C1s антитела. В данном изобретении предложены нуклеиновые кислоты, содержащие нуклеотидные последовательности, кодирующие гуманизированные анти-C1s антитела; и клетки-хозяева, содержащие данные нуклеиновые кислоты. В данном изобретении предложены композиции, содержащие гуманизированные анти-C1s антитела. В данном изобретении предлагаются способы применения гуманизированных анти-C1s антител.
EA201792080A 2015-04-06 2016-04-05 Гуманизированные анти-c1s антитела и способы их применения EA201792080A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562143636P 2015-04-06 2015-04-06
US201562200997P 2015-08-04 2015-08-04
PCT/US2016/026038 WO2016164358A1 (en) 2015-04-06 2016-04-05 Humanized anti-c1s antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
EA201792080A1 true EA201792080A1 (ru) 2018-03-30

Family

ID=57073330

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792080A EA201792080A1 (ru) 2015-04-06 2016-04-05 Гуманизированные анти-c1s антитела и способы их применения

Country Status (27)

Country Link
US (3) US10729767B2 (ru)
EP (2) EP3280440B1 (ru)
JP (4) JP7005483B2 (ru)
KR (2) KR102754975B1 (ru)
CN (2) CN117285634A (ru)
AU (2) AU2016246452B2 (ru)
BR (1) BR112017021289A2 (ru)
CA (1) CA2981321A1 (ru)
CL (1) CL2017002514A1 (ru)
CO (1) CO2017011238A2 (ru)
DK (1) DK3280440T5 (ru)
EA (1) EA201792080A1 (ru)
ES (1) ES2938359T3 (ru)
FI (1) FI3280440T3 (ru)
HK (1) HK1259251A1 (ru)
HR (1) HRP20230093T1 (ru)
HU (1) HUE061076T2 (ru)
IL (3) IL298180B2 (ru)
LT (1) LT3280440T (ru)
MX (2) MX389703B (ru)
PH (2) PH12017501815B1 (ru)
PL (1) PL3280440T3 (ru)
PT (1) PT3280440T (ru)
RS (1) RS63956B1 (ru)
SG (2) SG11201707886WA (ru)
SI (1) SI3280440T1 (ru)
WO (1) WO2016164358A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2889376A4 (en) 2012-08-24 2016-11-02 Chugai Pharmaceutical Co Ltd ANTIBODIES Fc SPECIFIC TO FCTRII OF MOUSE
EP2912065A4 (en) 2012-10-25 2016-10-19 True North Therapeutics Inc ANTI COMPLEMENT C1S ANTIBODIES AND USES THEREOF
GB2509260B (en) 2012-11-02 2016-05-04 True North Therapeutics Inc Anti-complement C1s antibodies and uses thereof
CN113621057A (zh) 2013-04-02 2021-11-09 中外制药株式会社 Fc区变体
SG11201707886WA (en) 2015-04-06 2017-10-30 True North Therapeutics Inc Humanized anti-c1s antibodies and methods of use thereof
PE20191031A1 (es) * 2016-10-12 2019-08-05 Bioverativ Usa Inc ANTICUERPOS ANTI-C1s Y METODOS DE USO DE LOS MISMOS
US12084513B2 (en) 2017-11-14 2024-09-10 Chugai Seiyaku Kabushiki Kaisha Anti-C1S antibodies and methods of use
KR20200143459A (ko) * 2018-04-13 2020-12-23 추가이 세이야쿠 가부시키가이샤 항-보체 성분 항체 및 사용 방법
EP4193153A1 (en) 2020-08-06 2023-06-14 Bioverativ USA Inc. Inflammatory cytokines and fatigue in subject with a complement mediated disease
CN117241828A (zh) 2021-03-31 2023-12-15 美国比奥维拉迪维股份有限公司 减少冷凝集素病患者的手术相关溶血
JP2024518844A (ja) * 2021-05-20 2024-05-07 ダイアンサス セラピューティクス オプコ， インコーポレイテッド Ｃ１ｓに結合する抗体およびその使用
CN117642431B (zh) 2021-07-13 2025-07-15 迈威(美国)生物治疗有限公司 抗c1s抗体和其用途
EP4539881A1 (en) 2022-06-15 2025-04-23 Bioverativ USA Inc. Anti-complement c1s antibody formulation
US20240025978A1 (en) 2022-06-24 2024-01-25 Bioverativ Usa Inc. Methods for treating complement-mediated diseases
US20240401082A1 (en) 2023-03-16 2024-12-05 Genzyme Corporation Treatment of Dry Age-Related Macular Degeneration

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS60192263A (ja) 1984-03-13 1985-09-30 Teijin Ltd 免疫複合体測定用標準物質及びそれを用いた免疫複合体の測定法
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0623679B1 (en) 1987-05-21 2003-06-25 Micromet AG Targeted multifunctional proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
EP0716611B1 (en) 1993-09-01 2002-02-06 Stichting Sanquin Bloedvoorziening C1-esterase inhibitor to reduce myocardial injury during acute myocardial infarction
ES2328585T3 (es) 1993-10-25 2009-11-16 Canji, Inc. Vector de adenovirus recombinante y metodo de utilizacion.
KR100551104B1 (ko) 1994-12-09 2006-02-09 임페리얼 컬리지 이노베이션스 리미티드 유전자의 동정
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
EP1152759A2 (en) 1999-02-09 2001-11-14 3-Dimensional Pharmaceuticals, Inc. METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR
WO2000064327A2 (en) 1999-04-26 2000-11-02 Duke University Inhibition of complement action
WO2001013945A1 (en) 1999-08-23 2001-03-01 Biocrystal Ltd. Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis
PT1252184E (pt) 2000-01-31 2008-04-15 Pharming Intellectual Pty Bv Inibidor humano c1 produzido no leite de mamíferos transgénicos
EP1265929B1 (en) 2000-03-23 2009-07-08 Genentech, Inc. Anti-c2/c2a inhibitors of complement activation
US7071299B2 (en) 2000-06-21 2006-07-04 Zymogenetics, Inc. Peptide and polypeptide inhibitors of complement C1s
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
WO2003009803A2 (en) 2001-07-26 2003-02-06 Alexion Pharmaceuticals Inc. Method of improving cognitive function
US20080206242A1 (en) 2002-03-01 2008-08-28 Xencor, Inc. Method of treatment of th2-mediated conditions using optimized anti-cd30 antibodies
SE0202880D0 (sv) 2002-07-26 2002-09-30 Wieslab Ab Complement system deficiency assay
US7666627B2 (en) 2002-08-08 2010-02-23 Targetex Kft. Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US20040115194A1 (en) 2002-09-06 2004-06-17 Yi Wang Method of treatment of asthma using antibodies to complement component C5
US7361339B2 (en) 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
ES2387275T3 (es) 2003-05-15 2012-09-19 Genentech, Inc. Métodos y composiciones para la prevención y el tratamiento de la sepsis
US7482376B2 (en) 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
WO2005014849A2 (en) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
US7923010B2 (en) 2003-09-11 2011-04-12 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
WO2005035754A1 (ja) 2003-10-14 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
EP2221315A1 (en) * 2003-12-04 2010-08-25 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
SG172616A1 (en) 2004-04-13 2011-07-28 Hoffmann La Roche Anti-p-selectin antibodies
EP3047858A1 (en) 2004-06-10 2016-07-27 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20060018896A1 (en) 2004-06-10 2006-01-26 University Of Leicester Methods for treating conditions associated with lectin-dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
JP2008523083A (ja) 2004-12-08 2008-07-03 イムノメディクス， インコーポレイテッド 炎症性疾患および免疫調節不全疾患、感染性疾患、病的血管新生およびがんの免疫療法および検出のための方法および組成物
ATE450522T1 (de) 2005-03-16 2009-12-15 Janssen Pharmaceutica Nv Neue thiophensulfoximine zur behandlung von komplementvermittelten krankheiten und leiden
WO2006131874A2 (en) 2005-06-06 2006-12-14 Univ Cape Town Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
KR101393946B1 (ko) 2005-10-21 2014-05-12 카탈리스트 바이오사이언시즈, 인코포레이티드 보체 활성화를 억제하는 변형된 프로테아제
US9480658B2 (en) 2005-12-09 2016-11-01 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
US8148330B2 (en) 2005-12-09 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
EP1965831B1 (en) 2005-12-21 2011-07-13 Pharming Intellectual Property B.V. Use of c1 inhibitor for the prevention of ischemia-reperfusion injury
FR2897868B1 (fr) 2006-02-24 2012-08-31 Lab Francais Du Fractionnement Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii.
RU2477137C2 (ru) 2006-03-08 2013-03-10 АРКЕМИКС Эл Эл Си Связывающие комплемент аптамеры и средства против с5, пригодные для лечения глазных нарушений
EP2913342A1 (en) 2006-09-05 2015-09-02 Alexion Pharmaceuticals, Inc. Compositions for use in the treatment of antibody mediated neuropathies
CA2980614A1 (en) 2006-10-10 2008-04-17 Regenesance B.V. Anti-sense oligonucleotide for use in facilitating axonal regeneration
CN101679219B (zh) 2006-12-19 2014-08-13 港大科桥有限公司 合成离子通道
AU2008214359B2 (en) 2007-02-05 2014-01-16 Apellis Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders
US8192742B2 (en) 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
NZ583367A (en) 2007-07-16 2012-10-26 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
CA2693852C (en) 2007-08-03 2016-11-29 Genentech, Inc. Humanized anti-fgf19 antagonists and methods using same
EP2278987A4 (en) 2008-03-28 2012-08-22 Apellis Ag MODULATION AND REPLY / IMPROVEMENT OF THE COMPLEMENTARY SYSTEM IN THE TREATMENT OF TRAUMATISM
CA2720682A1 (en) 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
WO2009151634A1 (en) 2008-06-12 2009-12-17 The Board Of Trustees Of The Leland Stanford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
SI2894165T1 (sl) 2008-11-10 2023-04-28 Alexion Pharmaceuticals, Inc. Postopki in sestavki za zdravljenje motenj povezanih s komplementom
CN102203610A (zh) 2008-12-01 2011-09-28 利兰·斯坦福青年大学托管委员会 用于检测补体结合性抗体的方法和组合物
US8401799B2 (en) 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
BRPI1012759A2 (pt) 2009-06-23 2019-07-02 Alexion Pharma Inc anticorpos biespecíficos que se ligam as proteínas do complemento.
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
SI2488203T1 (sl) 2009-10-16 2017-07-31 Omeros Corporation Metode za zdravljenje diseminirane intravaskularne koagulacije z inhibiranjem aktivacije masp-2 odvisnega komplementa
US8883985B2 (en) 2010-02-16 2014-11-11 National University Corporation Kyoto Institute Of Technology Antibody-immobilized carrier, method of producing antibody-immobilized carrier, and use of said antibody-immobilized carrier
WO2011109338A1 (en) 2010-03-01 2011-09-09 Alexion Pharmaceuticals Inc. Methods and compositions for treating degos' disease
MX340696B (es) 2010-04-30 2016-07-21 Alexion Pharma Inc Anticuerpos anti-c5a y metodos para usar los anticuerpos.
WO2011146514A2 (en) 2010-05-17 2011-11-24 The Board Of Regents Of The University Of Texas System Rapid isolation of monoclonal antibodies from animals
US9421240B2 (en) 2010-06-22 2016-08-23 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
AU2011270959A1 (en) 2010-06-22 2013-01-10 Musc Foundation For Research Development Antibodies to the C3d fragment of complement component 3
UY33578A (es) 2010-08-31 2012-03-30 Sanofi Sa PÉPTIDO O COMPLEJO PEPTÍDICO QUE SE UNE A INTEGRINA a(ALFA) Y MÉTODOS Y USOS QUE IMPLICAN A LOS MISMOS
TW201241008A (en) 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
US8865164B2 (en) 2010-11-02 2014-10-21 Kypha, Inc. Detecting complement activation
HUE031726T2 (en) 2010-12-06 2017-07-28 Seattle Genetics Inc Humanized antibodies to liv-1 and use of same to treat cancer
CA3237802A1 (en) 2011-04-08 2012-10-11 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
KR102024016B1 (ko) 2011-05-04 2019-11-04 오메로스 코포레이션 Masp-2 의존적 보체 활성화를 억제하는 조성물
US9289467B2 (en) 2011-08-10 2016-03-22 Case Western Reserve University Compositions and methods for treating bone conditions
JP6127063B2 (ja) 2011-12-22 2017-05-10 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 中枢神経系の続発性浮腫の治療のためのｃ１インヒビターの使用
JP6081699B2 (ja) 2011-12-28 2017-02-15 雅史 溝上 Ｉｌ−２８ｂの分析方法
EP2912065A4 (en) 2012-10-25 2016-10-19 True North Therapeutics Inc ANTI COMPLEMENT C1S ANTIBODIES AND USES THEREOF
GB2509260B (en) 2012-11-02 2016-05-04 True North Therapeutics Inc Anti-complement C1s antibodies and uses thereof
WO2014119969A1 (ko) 2013-01-31 2014-08-07 서울대학교 산학협력단 보체 관련 질환의 예방 및 치료를 위한 c5 항체 및 방법
HK1225678A1 (zh) 2013-07-09 2017-09-15 安尼艾克松股份有限公司 抗-補體因子c1q抗體及其應用
WO2015084999A1 (en) 2013-12-06 2015-06-11 True North Therapeutics, Inc. Complement component biomarker assays
SG11201707886WA (en) 2015-04-06 2017-10-30 True North Therapeutics Inc Humanized anti-c1s antibodies and methods of use thereof
NZ738570A (en) 2015-06-26 2025-05-02 Bioverativ Usa Inc Methods of treating autoimmune and alloimmune disorders
PE20191031A1 (es) 2016-10-12 2019-08-05 Bioverativ Usa Inc ANTICUERPOS ANTI-C1s Y METODOS DE USO DE LOS MISMOS
BR112019018950A2 (pt) 2017-03-14 2020-04-22 Bioverativ Usa Inc métodos para tratamento de doenças e distúrbios mediados por complemento

Also Published As

Publication number Publication date
IL254670A0 (en) 2017-11-30
LT3280440T (lt) 2023-02-27
JP2018513213A (ja) 2018-05-24
IL318523A (en) 2025-03-01
CA2981321A1 (en) 2016-10-13
EP3280440A4 (en) 2018-08-29
MX2022001085A (es) 2022-02-14
EP3280440A1 (en) 2018-02-14
CL2017002514A1 (es) 2018-04-20
AU2022203679A1 (en) 2022-06-16
HUE061076T2 (hu) 2023-05-28
JP7005483B2 (ja) 2022-02-10
PH12022551095A1 (en) 2023-02-27
BR112017021289A2 (pt) 2018-06-26
IL298180A (en) 2023-01-01
FI3280440T3 (fi) 2023-03-09
US11246926B2 (en) 2022-02-15
PH12017501815A1 (en) 2018-04-23
US20180092974A1 (en) 2018-04-05
RS63956B1 (sr) 2023-02-28
JP2022078221A (ja) 2022-05-24
US10729767B2 (en) 2020-08-04
IL254670B2 (en) 2023-04-01
PH12017501815B1 (en) 2023-09-20
JP7518114B2 (ja) 2024-07-17
MX389703B (es) 2025-03-20
KR20180006379A (ko) 2018-01-17
IL298180B2 (en) 2025-06-01
KR20250011240A (ko) 2025-01-21
ES2938359T3 (es) 2023-04-10
EP4212175A1 (en) 2023-07-19
IL254670B (en) 2022-12-01
WO2016164358A1 (en) 2016-10-13
IL298180B1 (en) 2025-02-01
AU2022203679B2 (en) 2025-07-17
CN108348598A (zh) 2018-07-31
SI3280440T1 (sl) 2023-03-31
KR102754975B1 (ko) 2025-01-14
JP7153696B2 (ja) 2022-10-14
HK1250930A1 (en) 2019-01-18
AU2016246452B2 (en) 2022-03-10
CO2017011238A2 (es) 2018-01-16
SG11201707886WA (en) 2017-10-30
MX2017012834A (es) 2018-05-28
DK3280440T5 (da) 2024-10-07
EP3280440B1 (en) 2022-11-16
US20200405852A1 (en) 2020-12-31
DK3280440T3 (da) 2023-02-20
JP2024133591A (ja) 2024-10-02
AU2016246452A1 (en) 2017-10-19
PL3280440T3 (pl) 2023-06-19
CN108348598B (zh) 2023-09-01
HRP20230093T1 (hr) 2023-03-31
CN117285634A (zh) 2023-12-26
SG10201909180SA (en) 2019-11-28
US20230218753A1 (en) 2023-07-13
JP2021006544A (ja) 2021-01-21
HK1259251A1 (zh) 2019-11-29
PT3280440T (pt) 2023-02-14

Similar Documents

Publication Publication Date Title
EA201792080A1 (ru) Гуманизированные анти-c1s антитела и способы их применения
PH12019500540A1 (en) Anti-pd-1 antibodies and their uses
CY1124806T1 (el) Αντισωματα enanti-cd40 και χρησεις αυτων
PH12019501357A1 (en) Anti-ox40 antibodies and their uses
EA201991383A1 (ru) Антитела против ctla-4 и способы их применения
MX2024015440A (es) Anticuerpos anti-phf-tau y usos de estos
EA201990884A1 (ru) АНТИ-C1s АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA201891532A1 (ru) Композиции и способы лечения гемоглобинопатий
EA201890630A1 (ru) Антитела против pd-1 и способы их применения
EA201891338A1 (ru) Композиции и способы для иммуноонкологии
MX381592B (es) Composiciones de detergente, variantes de lipasa y polinucleotidos que codifican las mismas.
EP3741848A3 (en) Protease variants and polynucleotides encoding same
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA202193002A2 (ru) Соединение, нацеленное на ил-23a и фно-альфа, и его применение
MX2024009271A (es) Constructos de anticuerpos de acidos nucleicos optimizados.
EA201791312A1 (ru) Способы мечения библиотек, кодируемых днк
MX2024000004A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
BR112018009097A2 (pt) spodoptera frugiperda resistente a vip3a
EA201990927A1 (ru) Антитела против lag-3 и способы их применения